Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Name :
Date: 29-Jul-2022
No. of pages: 161
Inquire Before Buying

Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Drugs In Development, 2022, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 13, 8, 19, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Endometriosis - Overview
Endometriosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Endometriosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Endometriosis - Companies Involved in Therapeutics Development
Endometriosis - Drug Profiles
Endometriosis - Dormant Projects
Endometriosis - Discontinued Products
Endometriosis - Product Development Milestones
Featured News & Press Releases
Oct 26, 2022: Enteris BioPharma announces acceptance of abstract for oral presentation at ASRM 2022 Scientific Congress & Expo
Jun 17, 2022: Myovant Sciences and Pfizer announce publication in The Lancet of phase 3 SPIRIT 1 and SPIRIT 2 studies of once-daily Relugolix combination therapy in women with endometriosis-associated pain
Jun 14, 2022: Enteris BioPharma presents data from two clinical studies involving oral formulations of leuprolide at ENDO 2022 Annual Conference
May 25, 2022: ObsEva presents clinical data on oral GnRH antagonist linzagolix at multiple congresses
May 09, 2022: Ironwood Pharmaceuticals to present new IW-3300 data at Digestive Disease Week 2022
May 09, 2022: FDA extends review period for Pfizer-Myovant's sNDA for Myfembree
Apr 28, 2022: BioInvent receives milestone payment from Bayer/Hope Medicine licensing agreement
Apr 12, 2022: Enteris BioPharma announces acceptance of two abstracts for presentation at ENDO 2022 Annual Conference
Apr 12, 2022: Myovant Sciences and Pfizer provide update on supplemental new drug application for MYFEMBREE for the management of moderate to severe pain associated with endometriosis
Mar 22, 2022: ObsEva announces additional efficacy results for linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
Jan 06, 2022: ObsEva announces positive topline results for Linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial in patients with moderate-to-severe endometriosis-associated pain
Dec 10, 2021: ObsEva hosts symposium and presents clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
Dec 02, 2021: ObsEva announces symposium and presentation of clinical data on oral GnRH antagonist Linzagolix at SEUD Congress 2021
Oct 19, 2021: Myovant Sciences and Pfizer present data on Relugolix combination therapy from studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
Oct 04, 2021: Enteris BioPharma announces successful completion of phase 1 clinical trial of optimized Peptelligence oral leuprolide
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Endometriosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Endometriosis - Pipeline by Abalone Bio Inc, 2022
Endometriosis - Pipeline by Aptorum Group Ltd, 2022
Endometriosis - Pipeline by Bayer AG, 2022
Endometriosis - Pipeline by BCI Pharma SA, 2022
Endometriosis - Pipeline by Bol Pharma, 2022
Endometriosis - Pipeline by Chugai Pharmaceutical Co Ltd, 2022
Endometriosis - Pipeline by Context Therapeutics Inc, 2022
Endometriosis - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Endometriosis - Pipeline by Egret Therapeutics Inc, 2022
Endometriosis - Pipeline by Eikonoklastes Therapeutics Inc, 2022
Endometriosis - Pipeline by ElexoPharm GmbH, 2022
Endometriosis - Pipeline by Endomet Biosciences Inc, 2022
Endometriosis - Pipeline by Enteris BioPharma Inc, 2022
Endometriosis - Pipeline by Eurofarma Laboratorios SA, 2022
Endometriosis - Pipeline by Evestra Inc, 2022
Endometriosis - Pipeline by Evotec SE, 2022
Endometriosis - Pipeline by Ferring International Center SA, 2022
Endometriosis - Pipeline by Forendo Pharma Ltd, 2022
Endometriosis - Pipeline by GeneScience Pharmaceuticals Co Ltd, 2022
Endometriosis - Pipeline by Hangzhou Metai Pharmaceutical Technology Co Ltd, 2022
Endometriosis - Pipeline by Hope Medicine Inc, 2022
Endometriosis - Pipeline by Immunitor Inc, 2022
Endometriosis - Pipeline by Insud Pharma, 2022
Endometriosis - Pipeline by Ironwood Pharmaceuticals Inc, 2022
Endometriosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, 2022
Endometriosis - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
Endometriosis - Pipeline by Medibiofarma SL, 2022
Endometriosis - Pipeline by Mithra Pharmaceuticals SA, 2022
Endometriosis - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Endometriosis - Pipeline by Myovant Sciences Ltd, 2022
Endometriosis - Pipeline by Navad Life Sciences Pte Ltd, 2022
Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, 2022
Endometriosis - Pipeline by Predictive Therapeutics LLC, 2022
Endometriosis - Pipeline by PregLem SA, 2022
Endometriosis - Pipeline by SYNG Pharmaceuticals Inc, 2022
Endometriosis - Pipeline by Synokem Pharmaceuticals Ltd, 2022
Endometriosis - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Endometriosis - Pipeline by Temple Therapeutics BV, 2022
Endometriosis - Pipeline by TiumBio Co Ltd, 2022
Endometriosis - Pipeline by ValiRx Plc, 2022
Endometriosis - Pipeline by Viramal Ltd, 2022
Endometriosis - Pipeline by Xbrane Biopharma AB, 2022
Endometriosis - Dormant Projects, 2022
Endometriosis - Dormant Projects, 2022 (Contd..1)
Endometriosis - Dormant Projects, 2022 (Contd..2)
Endometriosis - Dormant Projects, 2022 (Contd..3)
Endometriosis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Endometriosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
  • Global Drugs for Vulvovaginal Candidiasis Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119
    According to our LPI (LP Information) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at US$ 798.8 million in 2023. With growing demand in downstream market, the Drugs for Vulvovaginal Candidiasis is forecast to a readjusted size of US$ 890 million by 2030 with a CAGR of 1.6% during review period. The research report highlights the growth potential of the global Drugs for Vulvovaginal Candidiasis market. Drugs for Vulvovaginal Candidiasis are expected t......
  • Global Bacterial Vaginosis Drug Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 132
    According to our LPI (LP Information) latest study, the global Bacterial Vaginosis Drug market size was valued at US$ 896.6 million in 2023. With growing demand in downstream market, the Bacterial Vaginosis Drug is forecast to a readjusted size of US$ 1111.1 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Bacterial Vaginosis Drug market. Bacterial Vaginosis Drug are expected to show stable growth in the future ma......
  • Global Contraceptives Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 141
    According to our LPI (LP Information) latest study, the global Contraceptives market size was valued at US$ 1870.3 million in 2023. With growing demand in downstream market, the Contraceptives is forecast to a readjusted size of US$ 2237.4 million by 2030 with a CAGR of 2.6% during review period. The research report highlights the growth potential of the global Contraceptives market. Contraceptives are expected to show stable growth in the future market. However, product differentiation,......
  • Global Drugs for Vulvovaginal Candidiasis Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 108
    According to our (Global Info Research) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at USD 840.2 million in 2023 and is forecast to a readjusted size of USD 928.4 million by 2030 with a CAGR of 1.4% during review period. The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cu......
  • Global Menopausal Hot Flashes Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 99
    Market Overview of Global Menopausal Hot Flashes market: According to our latest research, the global Menopausal Hot Flashes market looks promising in the next 5 years. As of 2022, the global Menopausal Hot Flashes market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Hot flashes during menopause are symptoms of menopause. They refer to the warmth that occurs during the transition period of ......
  • Global Bacterial Vaginosis Drug Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 139
    Report Overview: This report studies the Bacterial Vaginosis Drug market, Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. This report includes metronidazole, clindamycin drug and other drugs. The Global Bacterial Vaginosis Drug Market Size was estimated at USD 916.50 million in 2022 and is projected to reach USD 1127.18 million by 202......
  • Global Drugs for Vulvovaginal Candidiasis Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 122
    Report Overview: The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for a......
  • Global Bacterial Vaginosis Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 108
    Market Overview of Global Bacterial Vaginosis Drug market: According to our latest research, the global Bacterial Vaginosis Drug market looks promising in the next 5 years. As of 2022, the global Bacterial Vaginosis Drug market was estimated at USD 972.77 million, and it's anticipated to reach USD 1215.68 million in 2028, with a CAGR of 3.79% during the forecast years. Bacterial vaginosis (BV), also known as bacterial vaginosis, non-specific vaginitis is a disease that occurs......
  • Global Tocolysis Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 123
    Market Overview of Global Tocolysis Drugs market: According to our latest research, the global Tocolysis Drugs market looks promising in the next 5 years. As of 2022, the global Tocolysis Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Tocolytics are medications used to suppress premature labor. Tocolytic therapy is provided when delivery would result in premature birth, postponi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs